These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions. Bibi N, Parveen Z, Rashid S. PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120 [Abstract] [Full Text] [Related]
5. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks. Mao XL, Wang KF, Zhu F, Pan ZH, Wu GM, Zhu HY. Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535 [Abstract] [Full Text] [Related]
9. Pinning down the polo-box domain. Lee KS, Idle JR. Chem Biol; 2008 May 10; 15(5):415-6. PubMed ID: 18482691 [Abstract] [Full Text] [Related]
10. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. Zhao XZ, Hymel D, Burke TR. Bioorg Med Chem; 2017 Oct 01; 25(19):5041-5049. PubMed ID: 28285924 [Abstract] [Full Text] [Related]
11. Crystallization and preliminary X-ray diffraction studies on the human Plk1 Polo-box domain in complex with an unphosphorylated and a phosphorylated target peptide from Cdc25C. García-Alvarez B, Ibañez S, Montoya G. Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Apr 01; 62(Pt 4):372-5. PubMed ID: 16582488 [Abstract] [Full Text] [Related]
12. Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. Qian W, Park JE, Liu F, Lee KS, Burke TR. Bioorg Med Chem; 2013 Jul 15; 21(14):3996-4003. PubMed ID: 22743087 [Abstract] [Full Text] [Related]
14. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain. Yan F, Liu G, Chen T, Fu X, Niu MM. Molecules; 2019 Dec 27; 25(1):. PubMed ID: 31892137 [Abstract] [Full Text] [Related]
16. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy. Shakil S, Baig MH, Tabrez S, Rizvi SMD, Zaidi SK, Ashraf GM, Ansari SA, Khan AAP, Al-Qahtani MH, Abuzenadah AM, Chaudhary AG. Semin Cancer Biol; 2019 Jun 27; 56():47-55. PubMed ID: 29122685 [Abstract] [Full Text] [Related]
17. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. Yin Z, Song Y, Rehse PH. ACS Chem Biol; 2013 Feb 15; 8(2):303-8. PubMed ID: 23135290 [Abstract] [Full Text] [Related]
18. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. Lasek AL, McPherson BM, Trueman NG, Burkard ME. PLoS One; 2016 Feb 15; 11(2):e0150225. PubMed ID: 26919439 [Abstract] [Full Text] [Related]
19. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells. Qian WJ, Park JE, Lim D, Lai CC, Kelley JA, Park SY, Lee KW, Yaffe MB, Lee KS, Burke TR. Biopolymers; 2014 Nov 15; 102(6):444-55. PubMed ID: 25283071 [Abstract] [Full Text] [Related]